Forxiga (dapagliflozin propanediol hydrate), an SGLT-2 class of diabetes treatment, will maintain its upper limit price until it leaves the South Korean market.

It appears that AstraZeneca’s strategy for defending the upper limit price through the court’s suspension of execution has worked. The price-value agreement (PVA) negotiations, which were the last variable to determine the drug’s listing price, will likely end without any changes.

According to industry sources on the 21st, Forxiga tab 10 mg will be deleted from the reimbursement listing as of June 1st as the company voluntarily withdrew approval on May 25th.

A grace period is set until December 1st. Unt